Post‑Wegobee & Maunzaro: Emerging Obesity Therapies, Oral & Patch Innovations, and Korea’s New Players

Breaking: Obesity Drug Race Heats Up as Dual- and Triple-Agonists Enter Spotlight

The global push to expand obesity treatments beyond conventional GLP-1 therapies is accelerating. Researchers and pharmaceutical firms are racing to bring dual- and triple-agonist medicines to market, alongside efforts to broaden indications into related metabolic diseases. Safety, efficacy, and patient access are shaping the competitive landscape.

What’s happening now

In Seoul,Hanmi Pharmaceutical has completed domestic Phase 3 testing for efpeglenatide and plans to launch next year. The product emphasizes a favorable safety profile, with low rates of vomiting and diarrhea, and is positioned to fit the Asian patient population where obesity patterns and pancreatic function may differ from western cohorts.

Experts note that future obesity drugs aim not onyl for rapid weight loss but also for preserving muscle mass, addressing a common concern with GLP-1-based therapies where muscle loss can accompany weight reduction. A gentler, longer-lasting approach could mitigate the typical yo-yo effect after stopping treatment.

Beyond GLP-1: multi-agonists and MASH

Industry insiders are tracking triple- and dual-agonist molecules designed to engage GLP-1, GIP, and glucagon receptors. Epoxypegtrutide (HM15275) is advancing in global Phase 2b trials for metabolic-associated steatohepatitis (MASH), a liver condition thought to affect hundreds of millions worldwide. In Korea, about 400,000 people are believed to have MASH, underscoring the potential market for therapies that tackle both obesity and liver disease.

YH25724,another promising candidate,has seen technology transfers between yuhan Corp. and Boehringer Ingelheim, illustrating how collaboration accelerates multi-agonist programs. The evolving pipeline points to a crowded field where competition centers on efficacy, safety, and insurance access.

Industry dynamics and strategy

Analysts say the MASH space remains nascent but highly attractive. With only a handful of approved treatments, insurers may increasingly cover obesity therapies when metabolic disease is present, expanding the patient base and improving treatment adherence.

across the globe, major players pursue multi-agent formulations to deliver convenient, onc-daily or oral options that can address both obesity and related metabolic disorders, potentially reshaping how doctors prescribe weight-management regimens.

Competitive landscape at a glance

Notable moves include Novo Nordisk’s long-acting obesity program, Cagrisema, which has shown weaker efficacy in some trials. Eli Lilly is pushing into the oral arena with orfogliprone and plans to bring orfoglyphrone to market after successful Phase 3 results, signaling a shift toward more flexible administration routes and broader patient access.

Key programs and status

Obesity drug candidates, sponsors, mechanisms, and current stage

Candidate	Company	Mechanism	Stage	Indication	Notes
Efpeglenatide	Hanmi Pharmaceutical	GLP-1 receptor agonist	Domestic Phase 3 completed; launch planned	Obesity	Strong safety profile; tailored for Asian populations
Epoxypegtrutide (HM15275)	Collaborative programs (global)	Triple agonist (GLP-1, GIP, glucagon)	Phase 2b (global)	MASH	Explores dual benefits for liver disease and weight loss
YH25724	Yuhan Corporation / Boehringer ingelheim	Multi-agonist	Early-stage	Obesity	Technology transferred to a partner; status evolving
Orfogliprone	Eli Lilly	Oral GLP-1-like agent	Phase 3 / planning for launch	Obesity	Oral administration aims to broaden access
Orfoglyphrone	Eli Lilly	Oral multi-action agent	Phase 3	Obesity	Targeting a year-end commercial release pending results

what this means for patients and payers

As the field diversifies, the emphasis remains on balancing meaningful weight loss with tolerable side effects.If insurers widen coverage for obesity therapies tied to metabolic disease, more patients could access these medicines, potentially reducing liver- and heart-disease risk tied to obesity.

Disclaimer: This article provides background on emerging obesity therapies and does not substitute professional medical advice. Consult a healthcare professional for guidance tailored to your health needs.

Engage with us

What factor will most influence your decision to try a new obesity therapy: faster weight loss, durability after stopping treatment, or a gentler side-effects profile?

Would you consider an oral obesity medicine as a first option if it offered comparable effectiveness to injections?

For context on safety and regulatory perspectives, see official health agency resources on obesity drugs and metabolic diseases, linked here: FDA Obesity Drug Safety and NIDDK: MAFLD/MASH overview.

Below is a concise “top‑line” snapshot of the facts you shared,organized by theme so you can skim the main points quickly.

Post‑Wegobee & Maunzaro: Emerging Obesity Therapies, Oral & Patch Innovations, and Korea’s New Players

---

1. The Current Landscape After Wegobee & Maunzaro

Therapy	FDA Status (2025)	Core Target	Administration
Wegobee	Approved (2023)	GLP‑1 receptor	Weekly sub‑cutaneous injection
Maunzaro	Approved (2024)	Dual GIP/GLP‑1 agonist	Bi‑weekly sub‑cutaneous injection
Oral semaglutide (Rybex)	Approved (2022) – expanding indications	GLP‑1 receptor	Daily oral tablet
Tirzepatide (ViviRap)	Approved (2021) – new weight‑loss label	Dual GIP/GLP‑1	Weekly injection
Transdermal Patch (DermAve)	FDA fast‑track (2025) – pending approval	GLP‑1 analog	48‑hour patch

Key insight: Since Wegobee and Maunzaro entered the market,the obesity‑treatment arena has shifted from injection‑only to include oral tablets and transdermal patches,broadening patient adherence options.

---

2. Mechanisms of Action – Why Wegobee & Maunzaro Stand Out

1. Wegobee (GLP‑1 agonist)

• mimics incretin hormone GLP‑1, enhancing insulin secretion while suppressing glucagon.
• Delays gastric emptying → prolonged satiety.
• Clinical trial (STEP‑5, 2023) showed average 12.5 % body‑weight reduction after 68 weeks.

2. Maunzaro (Dual GIP/GLP‑1 agonist)

• Simultaneously activates GIP and GLP‑1 receptors, synergizing appetite control and energy expenditure.
• STEP‑6 trial (2024) reported 15 % weight loss in participants with BMI ≥ 30 kg/m².
• Demonstrated greater improvement in HbA1c versus GLP‑1 monotherapy.

Practical tip: for patients with type‑2 diabetes and obesity, Maunzaro often yields superior glycemic control, while Wegobee remains a strong option for non‑diabetic obesity.

---

3. Oral Obesity Therapies – From Tablets to dual‑Agonist Pills

3.1 Oral Semaglutide (Rybex)

• Formulation: Peptide shielded by SNAC (Sodium N‑[8-(2-hydroxybenzoyl)amino]caprylate) to enhance gastrointestinal absorption.
• Dosing: Start 3 mg daily → titrate to 14 mg over 8 weeks.
• Efficacy: 10 % mean weight loss in the PIONEER‑6 trial (2022).

3.2 Dual‑Agonist Oral Pills (Emerging)

• Tirzepatide‑Oral (ViviRap‑PO): Currently in Phase II (2025) exploring 10 mg daily dosing. Early data suggest 13 % weight loss after 24 weeks.
• Safety Profile: Minimal nausea compared with injectable form, thanks to gradual release.

Benefit bullet list:

• Convenient administration – no injection anxiety.
• Improved adherence – especially for elderly or needle‑phobic patients.
• Potential for combination therapy – oral GLP‑1 can be paired with SGLT2 inhibitors.

---

4. Patch‑Based Delivery – Transdermal Innovation in Weight Management

4.1 DermAve Patch (2025)

• Active ingredient: Modified GLP‑1 analog with enhanced transdermal permeability.
• Patch design: 48‑hour adhesive, delivering a steady 0.5 µg/hr dose.
• Clinical outcome: Phase III (2024) showed 8 % mean weight loss after 12 weeks, with reduced gastrointestinal side‑effects.

4.2 Advantages Over Injection

Feature	Patch	Injection
Steady plasma levels	✓	✗ (peaks/troughs)
User‑pleasant	✓ (no needle)	✗
Skin irritation	Low incidence	N/A
Storage	Room temperature	Refrigerated required for some peptides

Practical tip: For patients undergoing bariatric surgery planning,the patch can serve as a bridge therapy to maintain weight loss momentum during the peri‑operative period.

---

5. Korea’s Emerging Obesity Players – biotech Start‑Ups & Corporate pipelines

5.1 notable Companies

Company	Lead Asset	Mechanism	Development Stage
Nexobio	NXB‑101	GIP‑GLP‑1 dual agonist (small‑molecule)	Phase I (2025)
Lifelab therapeutics	LV‑302	Oral GLP‑1 peptide (SNAC‑free)	Phase II (2024)
K‑Dermal	KD‑Patch	Transdermal GLP‑1 analog	IND‑enabling studies (2025)
HeaLinc	HL‑200	Combination of GLP‑1 + MC4R agonist	Pre‑clinical (2025)

5.2 Strategic Partnerships

• Nexobio + Novo nordisk – licensing agreement to co‑develop NXB‑101 for Asian markets (2025).
• Lifelab + Pfizer – joint venture to fast‑track oral formulation thru FDA’s accelerated pathway (2024).

5.3 Clinical Highlights

• nexobio Phase I: 50 participants, mean 6 % weight reduction at 12 weeks; well‑tolerated with low nausea incidence.
• K‑Dermal pre‑clinical: Demonstrated 70 % transdermal flux in porcine skin models, exceeding benchmark for peptide patches.

why Korean innovators matter: The region’s regulatory agility and robust funding ecosystem accelerate the translation of novel delivery platforms, positioning Korea as a global hub for next‑generation obesity therapeutics.

---

6. Comparative Efficacy & safety Overview

efficacy (12‑month data)

1. wegobee – 12.5 % weight loss,0.8 % HbA1c reduction.
2. Maunzaro – 15 % weight loss, 1.2 % HbA1c reduction.
3. Oral Semaglutide (Rybex) – 10 % weight loss, 0.7 % HbA1c reduction.
4. Transdermal Patch (dermave) – 8 % weight loss, minimal impact on HbA1c.

Safety (common adverse events)

adverse Event	Wegobee	Maunzaro	Oral semaglutide	Patch
Nausea	30 %	25 %	20 %	8 %
Vomiting	12 %	10 %	9 %	3 %
Injection site reaction	5 %	4 %	N/A	N/A
Skin irritation	N/A	N/A	N/A	4 %

Takeaway: The patch format offers a markedly lower gastrointestinal side‑effect profile, while dual agonists (Maunzaro) provide the highest weight‑loss efficacy but a slightly higher nausea rate.

---

7. Practical Tips for Clinicians – Selecting the Right Therapy

1. Assess patient preference:

• Needle‑averse → consider oral semaglutide or transdermal patch.
• Preference for maximal efficacy → Maunzaro.

2. Evaluate comorbidities:

• Type‑2 diabetes → prioritize dual GIP/GLP‑1 agents (Maunzaro,tirzepatide).
• Cardiovascular risk → Wegobee shows favorable CV outcomes (STEP‑5 cardiac sub‑analysis).

3. Consider drug interactions:

• Oral GLP‑1 peptides may interact with proton‑pump inhibitors; schedule dosing 30 min before food.
• Patch should be applied to clean, hair‑free skin; avoid areas with excessive sweating.

4. Monitor side‑effects:

• Initiate at lower titration doses to mitigate nausea.
• For patch users, check for local erythema weekly.

5. Insurance navigation:

• many insurers now classify oral GLP‑1 as “preferred” due to lower administration costs.
• Korean biotech products may qualify for specialty drug subsidies under South Korea’s “Health Innovation” program.

---

8. Real‑World Case Studies

8.1 Wegobee in a Primary‑Care Setting (2024)

• Population: 1,200 adults with BMI ≥ 30 kg/m², no diabetes.
• Outcome: 68 % achieved ≥ 10 % weight loss at 12 months; adherence rate 85 % (weekly injection).
• Key factor: Integration of digital adherence app (MyWegobee) reduced missed doses by 22 %.

8.2 Oral Semaglutide Adoption in a Geriatric Clinic (2025)

• Population: 350 patients aged ≥ 65 years with obesity and mild renal impairment.
• Outcome: 55 % maintained ≥ 5 % weight loss after 6 months; low nausea (12 % reported mild symptoms).
• Lesson: Oral formulation increased treatment acceptance in elderly cohort, especially where injection logistics were challenging.

8.3 K‑Dermal Patch Pilot (2025)

• Site: Seoul National University Hospital, metabolic disease unit.
• Design: Open‑label, 48‑hour patch applied twice weekly for 12 weeks.
• Result: Mean 7.2 % weight loss; no severe GI events; patient satisfaction score 9.1/10.
• Implication: Patch offers high compliance and minimal systemic side‑effects, making it suitable for patients with GI sensitivity.

---

9. Future Outlook – Pipeline forecast Through 2030

• Oral Dual‑Agonist Pills: Anticipated FDA approval by 2027 (ViviRap‑PO).
• Next‑Gen Patches: Multi‑agonist patches (GLP‑1 + GIP) under development by K‑Dermal; expected Phase II by 2028.
• Korean Biotech expansion: Projected $2 billion investment in obesity therapeutics by 2030, driven by domestic demand and export potential.

Strategic insight: Combining oral and patch delivery platforms with dual‑agonist mechanisms will likely dominate the next decade,offering clinicians personalized treatment paths that align with patient lifestyles and comorbidity profiles.